A Non-interventional, Multi Center, Prospective Observational Study to Evaluate the Effect of Improving Systolic Blood Pressure and Low-density Lipoprotein Cholesterol Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab. in Patients With Essential Hypertension and Dyslipidemia
Latest Information Update: 22 May 2025
At a glance
- Drugs Olmesartan medoxomil/rosuvastatin (Primary)
- Indications Dyslipidaemias; Essential hypertension
- Focus Therapeutic Use
- Sponsors Daewoong Pharmaceutical
Most Recent Events
- 15 May 2025 Planned End Date changed from 31 May 2025 to 30 Jun 2025.
- 12 Mar 2025 Planned primary completion date changed from 1 Feb 2025 to 31 Mar 2025.
- 22 Jan 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Feb 2025.